Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Carboplatin|DRUG: Nivolumab
Sponsor: Dana-Farber Cancer Institute
Collaborators: Bristol-Myers Squibb